The Safety and Efficacy of a Peanut Immunotherapy Dissolving Film for Peanut Allergy
Overview
- Phase
- Phase 1
- Status
- Terminated
- Sponsor
- Johns Hopkins University
- Enrollment
- 5
- Locations
- 2
- Primary Endpoint
- The Proportion of Subjects That Discontinue the Study for Treatment Related Reasons
Overview
Brief Summary
The purpose of this study is to determine if a new method of administration of peanut sublingual immunotherapy, a dissolving peanut film, is effective.
Detailed Description
Peanut allergy is a common problem with no current treatment. Recent studies have shown some success with oral or sublingual immunotherapy for the treatment of food allergy. Oral treatment, which requires very high doses, is associated with a small but appreciable risk of systemic reactions. Sublingual immunotherapy, which utilizes much smaller doses, is safer but constraints inherent in the available methods of sublingual administration have limited the utility of this method. Typically sublingual immunotherapy for food allergy has used either fresh foods or a simple liquid extract. These methods are not optimized for practicality or dwell duration in the mouth, and, thus far, dosing has been limited by the ability to make concentrated extracts and by the volume of extract that can be applied to the sublingual space. This study is being conducted to determine if a dissolving peanut extract film, will improve efficacy for immunotherapy for peanut allergy.
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 50 Years (Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Age 18 to 50 years
- •Provide signed informed consent
- •Using appropriate birth control if subject is female and of child bearing age
- •Are available for the study duration
- •Healthy Volunteers Only
- •Regularly consume a meal sized portion (5 grams) of peanut at least twice per month during the proceeding 6 months
- •Peanut Allergic Subjects Only
- •Have a history of symptomatic reactivity to peanut
- •Have a positive skin prick test
- •Have a positive oral food challenge to peanut at a cumulative dose of less than 1 grams of peanut protein
Exclusion Criteria
- •Have a history of severe anaphylaxis to peanut, defined as hypoxia, hypotension or neurological compromise as a result of ingestion of peanut.
- •Have a history of intubation related to asthma
- •Are pregnant or lactating
- •Have a viral Upper Respiratory Infection (URI) or gastroenteritis within 7 days of Oral food challenge
- •Have pulmonary function tests \<80% of predicted (FEV1) or clinical history consistent with more than moderate persistent asthma
- •Are currently taking greater than medium dose inhaled corticosteroid (\>500 mcg/day fluticasone or fluticasone equivalent)
- •Are unable to discontinue antihistamines for 5 days for long acting and 3 days for short acting prior to skin testing or food challenges
- •Have used systemic corticosteroids within 4 weeks prior to baseline visit
- •Are receiving omalizumab, beta-blocker, Angiotensin Converting Enzyme (ACE) inhibitor or tricyclic antidepressant therapy. Subjects need to be off omalizumab for 6 months.
- •Have history of oral cancer.
Arms & Interventions
Peanut Allergic
Only one intervention will be given. Peanut allergic study subjects, will receive gradually increasing doses of the dissolving peanut film.
Intervention: Peanut Dissolving Film (Drug)
Healthy Volunteers
Healthy volunteers will receive active peanut dissolving films in an expedited manner in order to determine safety dissolving films.
Intervention: Peanut Dissolving Film (Drug)
Outcomes
Primary Outcomes
The Proportion of Subjects That Discontinue the Study for Treatment Related Reasons
Time Frame: 18 months
No healthy volunteers discontinued the study for treatment related reasons. No active participants enrolled.
Secondary Outcomes
- The Proportion of Subjects Who Are Able to Tolerate the Full 10 Gram Peanut Protein Challenge at the Completion of the Study(18 months)
- Number of Participants With Serious and Non-serious Adverse Effects With Therapy(18 months)
- The Rate of Medication Use With Therapy(18 months)
- Changes in Biomarkers (Peanut Specific Immunoglobulin E (IgE) and Immunoglobulin G (IgG), Basophil Reactivity, and Salivary Biomarkers) From Baseline to the End of Therapy(18 months)
- Number of Participants With Serious Adverse Events With Dosing(18 months)